X-Chem announced a multi-target pharma deal with Pfizer.
The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases.
X-Chem is applying its discovery engine, which leverages a high diversity, proprietary DNA-encoded small molecule library to seek the identification of novel leads for the Pfizer programs.
Pfizer has an exclusive option to license any compounds generated in the course of the collaboration.
The financial terms of the agreement were not disclosed.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Pfizer
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity